Results 141 to 150 of about 5,328 (181)

The Evolving Interplay Between Targeted Therapy and Surgery for Resectable Lung Cancer. [PDF]

Cancers (Basel)
Yin V, Antonoff MB.
europepmc   +1 more source

Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma. [PDF]

Head Neck
Nagano A, Matoba T, Kawakita D, Minohara K, Iwaki S, Tsuge H, Tsukamoto K, Kikuchi S, Nakano S, Murase T, Tada Y, Iwasaki S.   +11 more
europepmc   +1 more source

Population-Adjusted Indirect Treatment Comparisons of Repotrectinib Among Patients with <i>ROS1+</i> NSCLC. [PDF]

Cancers (Basel)
Wolf J, Goring S, Lee A, Cho BC, Drilon A, Yuan Y, Ayers D, Lozano-Ortega G, Korol EE, Korpach SG, Crabtree M, Huria L, Calvet CY, Camidge DR.   +13 more
europepmc   +1 more source

Fusion-Negative NTRK Overexpression Exhibit Biological Relevance in Colorectal Cancer: Implications for Prediction of Responses to Kinase Inhibitors. [PDF]

Pharmaceuticals (Basel)
Alfahed A.
europepmc   +1 more source

Entrectinib-Induced Pericarditis with Cardiac Tamponade in a Patient with Neurotrophic Tropomyosin Receptor Kinase 1 Fusion-Positive Breast Cancer. [PDF]

Case Rep Oncol
Aoyama A, Yoshitomi Y, Shimomura A, Kawamura Y, Taniyama T, Kurozumi A, Kubota S, Hiroi Y, Shimizu C.   +8 more
europepmc   +1 more source

In-silico identification of host-key-genes associated with dengue-virus-infections highlighting their pathogenetic mechanisms and therapeutic agents. [PDF]

PLoS One
Latif MA, Noman MA, Ahmmed R, Hossain MS, Ahmed MF, Pappu MAA, Islam MS, Noor T, Kabir MH, Mollah MNH.   +9 more
europepmc   +1 more source

Novel NOTCH2-NTRK1 fusion confers osimertinib resistance in EGFR-mutant non-small cell lung cancer by interacting with EGFR. [PDF]

Transl Oncol
Li H, Wei H, Zhen T, Gao H, Liu H, Zheng S, Shi H, Liang J, Zhang F, Ye J, Lin G, Han A.   +11 more
europepmc   +1 more source

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment. [PDF]

Pharmaceut Med
Kong L, Grobman B, Mansur A, Lee A, Bondarchuk C, Erdogan H, Lu CY.   +6 more
europepmc   +1 more source

Rare but not forgotten: Therapeutic advancements for rare childhood cancers. [PDF]

Mol Ther Oncol
Crane JN, Dagalakis U, Gartrell RD, Schultz KAP, Laetsch TW.   +4 more
europepmc   +1 more source

Taletrectinib in ROS1-positive NSCLC: bridging clinical trials and real-world practice. [PDF]

Ann Med Surg (Lond)
Zahra FT, Naveed F, Fatima M.
europepmc   +1 more source